Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Did the Pattern of Practice in the Prescription of Palliative Radiotherapy for the Treatment of Uncomplicated Bone Metastases Change between 1999 and 2005 at the Rapid Response Radiotherapy Program?

N. M. E. Bradley*, J. Husted†, M. S. L. Sey§, E. Sinclair¶, K. K. Li**, A. F. Husain§∥, C. Danjoux¶¶, E. A. Barnes¶¶, M. N. Tsao¶¶, L. Barbera¶¶, K. Harris*, H. Chiu*, M. Doyle*, E. Chow¶¶

*Department of Health Studies and Gerontology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, Ontario, Canada; †Rapid Response Radiotherapy Program, Odette Cancer Centre, Toronto, Ontario, Canada; §Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; ¶Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; ||Temmy Latner Centre for Palliative Care, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; ¶¶Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

ABSTRACT:

Aims: Since 1999, randomised clinical trials and meta-analyses have reported equal efficacy of pain relief from single- and multiple-fraction radiotherapy for bone metastases. A number of factors, including limited radiotherapy resources, waiting times, and patient convenience, suggest single fraction to be the treatment of choice for patients. However, international patterns of practice indicate that multiple fractions are still commonly used. This study examined whether dose-fractionation schemes used for the treatment of bone metastases at the Rapid Response Radiotherapy Program (RRRP) at the Odette Cancer Centre have changed since 1999.

Materials and methods: A retrospective review of the prospective RRRP database and hospital records were conducted for all patients treated with palliative radiotherapy for uncomplicated bone metastases at the RRRP in 1999 (or baseline), 2001, 2004 and from 1 January to 31 July 2005. Data were collected on patient demographics and clinical characteristics.

Results: Of the 693 patients, 65 and 35% were prescribed single fraction (predominantly single 8 Gy) and multiple fractions (predominantly 20 Gy/five fractions), respectively. The administration of single treatments generally increased over time, from 51% in 1999 to 66% in 2005 ($P = 0.0001$). On the basis of multiple logistic regression analyses, patients were more likely to be prescribed single-fraction radiotherapy if they had prostate cancer, had a poorer performance status, were treated to the limbs, hips, shoulders, pelvis, ribs, scapula, sternum, or clavicle (compared with the spine), were treated by a radiation oncologist who had been trained in earlier years, and who were treated after 1999.

Conclusions: Between 1999 and 2005, the use of single-fraction radiotherapy increased, corresponding to publications showing equal efficacy of pain relief between single and multiple fractions in the management of uncomplicated bone metastases. However, about a third of patients still received multiple fractions. Bradley, N. M. E. et al. (2008). Clinical Oncology 20: 327–336

© 2008 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Key words: Bone metastases, dose fractionation, knowledge translation, palliative, patterns of practice, radiotherapy

Introduction

It is estimated that about 50% of cancer patients will receive palliative radiotherapy during the course of their disease [1]. Radiotherapy is highly effective and therefore commonly used in the palliation of bone metastases, with an overall and complete pain response rate of 70 and 30%, respectively [2–4]. However, controversy exists on the optimal dose-fractionation regimen for the treatment of bone metastases [5,6]. Many randomised clinical trials (RCTs) on dose-fractionation schedules have concluded that a single fraction provides equal pain relief as multiple fractions in the treatment of uncomplicated bone metastases [3,7–15]. The first two large, multicentre RCTs confirming equivalence were published in 1999 [3,8], and were followed by the publication of two meta-analyses of 12 studies in 2003 [4,16]. On the basis of these empirical results, in 2004 the Province of Ontario published...
evidence-based guidelines that recommended the use of single-fraction radiotherapy in the management of uncomplicated bone metastases [17]. However, contemporary surveys on the patterns of practice in North America, Europe, Australia and Southeast Asia suggested that radiation oncologists continue to use multiple fractions in the treatment of bone metastases [18–31].

Meanwhile, shortages in radiotherapy resources, including health care professionals, technicians and radiation equipment, have historically led to a situation of overload in Ontario, where the delivery of timely radiotherapy was compromised [32,33]. This was evident by increased waiting times for radiation services, a concern for provincial health policy decision-makers, clinicians, and patients. Limited resources may be better used if patients with bone metastases are treated with a single fraction assuming equivalence of single and multiple fractions of radiotherapy in providing pain relief [34]. Moreover, two of the three surveys on patient preference showed that patients preferred the most convenient and effective treatment modality and most preferred shorter courses of palliative radiotherapy for bone metastases [35,36].

The Odette Cancer Centre is one of two large cancer centres providing radiotherapy in the Greater Toronto Area. The Rapid Response Radiotherapy Program (RRRP) is an outpatient clinic at the Odette Cancer Centre that started in 1996 as a pilot programme in Ontario to provide timely palliative radiotherapy and to reduce waiting times for radiotherapy services in Ontario [37]. Patients with advanced cancer are referred to the programme to relieve suffering and to improve symptoms and quality of life. About 70% of referrals to the RRRP are patients with painful bone metastases [37]. Most patients begin treatment on the day of initial consultation with the radiation oncologist. Therefore, if patients are prescribed a single fraction, they will typically be in the cancer centre for 1 day only.

This study was conducted to determine whether fractionations used for the treatment of uncomplicated bone metastases at the RRRP changed between 1999 and 2005. This will determine if evidence-based research findings are translated into clinical practice among radiation oncologists specialising in palliative radiotherapy at a large radiation treatment centre in Ontario. The effect of patient, disease, treatment, and organisational factors on the use of single vs multiple courses of palliative radiotherapy will also be considered.

Materials and Methods

A retrospective review of the prospective database of electronic treatment records and physician-dictated progress notes was conducted for all bone metastases patients who were prescribed palliative radiotherapy at the RRRP in 1999, 2001, 2004 and from 1 January to 31 July 2005. These years were chosen because they included time periods before and after the publication of the landmark RCTs and meta-analyses. Data from patient charts before 1999 were not available in electronic form so could not be included in the review. The year of 2001 was selected as an intermediary year used to determine changes in radiotherapy prescription after the publication of the two RCTs; as such, data from 2000 and 2002 were not collected. Data from 2003 were not collected given the severe acute respiratory syndrome (SARS) outbreak in Toronto, a period when radiation oncologists were more likely to prescribe single-fraction radiotherapy due to the increased chance of infection with longer stays in hospital. Furthermore, data were collected only until 31 July for 2005, given the time constraints of the data collection process. The primary outcome of interest was the dose-fractionation regimen prescribed (Gy/number of fractions).

Eight demographic and clinical variables shown to be associated with the dose-fractionation regimens prescribed were extracted from the medical records, including gender, age at radiation for bone metastases, primary cancer site, Karnofsky Performance Status (KPS) score [38] (if recorded at the time of consultation), distance from residence (derived from residential postal code) to cancer centre, bony site irradiated, and the year of certification with the Royal College of Physicians and Surgeons of Ontario each radiation oncologist.

Primary cancer sites were categorised as cancer of the lung, breast, prostate, and others. The KPS is a validated functional assessment tool often used for oncology patients, with an 11-point categorical interval scale ranging from 0 (death) to 100 (no functional impairment) [38]. KPS scores were analysed as a continuous variable. The distance travelled from residence to cancer clinic was summarised: (1) continuously; (2) as an ordinal categorical variable as: near (0 to <40 km), intermediate (>40 to <80 km), distant (>80 to <120 km), and very distant (>120 km); and (3) as a dichotomous variable as: near (0 to <45 km) and distant (>45 km). Irradiated bone metastases sites were grouped into five categories: (1) spine; (2) pelvis; (3) ribs, scapula, sternum and clavicle (chest); (4) limbs, hips, and shoulders; and (5) skull and hemi-body irradiation. The year of certification for the treating radiation oncologist was recorded for each patient case and was categorised by decade: 1970–1979; 1980–1989; 1990–1999; 2000–2005.

Excluded from the analysis were patients who had documented spinal or cauda equina compression, nerve root impingement, actual or impending pathological fracture(s) of an extremity, previously irradiated bony lesions, or referrals for postoperative radiotherapy to the bone. Any uncertainty of the presence of spinal cord compression, pathological fracture, or impending cord compression and fracture were cross-checked with available imaging reports. Data were collected for each episode of radiotherapy for bone metastases in 1999, 2001, 2004 and 1 January to 31 July 2005. Ethical approval for research involving humans was obtained from the hospital Research Ethics Board.
**Statistical Analyses**

Descriptive statistics were recorded as percentages for proportions and as means, medians, standard deviations, and ranges for continuous variables. For the purpose of this study, the dose-fractionation regimen for each patient was coded as a binary variable, where 1 = single fraction and 0 = multiple fractions. For patients who had more than one independent course of radiotherapy for bone metastases during the study period, one course of radiation was randomly selected using a table of random numbers. To determine whether the use of single-fraction radiotherapy changed over time, the chi-square test was used. The chi-square test was also used to detect differences in proportions between unordered categorical variables, including gender, travel distance, primary cancer site, site of radiotherapy, prescription of single or multiple fractions, radiation oncologist, and year of certification of radiation oncologist across time. Continuous interval variables, such as age and travel distance, were tested across time using the analysis of variance (ANOVA). Univariate logistic regression analyses were conducted to identify patient, treatment, and organisational variables significantly associated ($P \leq 0.05$) with the use of single-fraction regimens. In these models, multilevel categorical variables were dummy coded with the following reference groups: female for gender; lung for primary cancer site; near for travel distance; spine for radiotherapy site group; and 2000–2005 for year of certification of radiation oncologist. We then carried out a multiple logistic regression analysis to examine the effect of the year of treatment (1999 was the referent group) on the use of single radiotherapy, after adjusting for gender, age, primary cancer site, KPS, travel distance to cancer centre, site of radiotherapy, and year of certification of radiation oncologist. Covariates were included in the final model if they were hypothesised to be related to the prescription of single-fraction radiation across time and the final model was selected based on the highest $R^2$ value, a statistical indicator of the best fit of a model. Patients with missing values for any covariates were excluded from the multiple logistic regression analysis.

Multi-collinearity was assessed using correlation coefficients, variance inflation factors, and condition indices. The Hosmer–Lemeshow goodness-of-fit test was conducted to determine if the data fitted the specified model [39]. All analyses were carried out using the Statistical Analysis System (SAS), version 9.1.3. Tests were considered statistically significant if the $P$ value was $\leq 0.05$, if the 95% confidence interval did not include one, and all tests were two-sided.

**Results**

The study sample consisted of 693 patients with symptomatic, uncomplicated bone metastases. In total, 965 courses of palliative radiotherapy were prescribed. Table 1 presents the clinic activity, demographic, disease and treatment-related characteristics of the patients for each year under study. Clinic activity refers to the number of patients who were prescribed radiotherapy for bone metastases as well as the number of courses of radiotherapy for bone metastases prescribed for each year under study. After randomly selecting one course of radiotherapy per patient, 451 (65.08%) and 242 (34.92%) patients were prescribed single and multiple fractions of radiation, respectively. Single-fraction treatments were predominantly prescribed as 8 Gy (92%), with doses ranging from 4 to 10 Gy. Ninety per cent of multiple-fraction treatments were prescribed as 20 Gy/five fractions and 6% were 30 Gy/10 fractions (range 12 Gy/two fractions to 30 Gy/10 fractions). The proportions of single fractions used over time are presented in Fig. 1. The administration of single treatments generally increased across time, from 51% in 1999, to 70% in 2001, to 71% in 2004 and 66% in 2005 ($P < 0.0001$).

Overall, 57% of the sample were men, with a mean age of 67.4 years. The three most common primary cancer sites were lung, prostate and breast (respectively), and the median KPS score was 60, indicating that most patients required occasional assistance from others, but were able to care for most needs [38]. About 87% of radiotherapy episodes were to the spine, pelvis, or limbs. The median travel distance to the clinic was 25.1 km and most patients (66.1%) resided ‘near’ the cancer centre (at a distance of less than 40 km). Tests for heterogeneity found significant differences in the proportion of men and women who were prescribed radiotherapy ($P = 0.037$) across time, with the proportion of men increasing. The distribution of primary cancer sites also changed ($P = 0.004$) across time, with an increasing proportion of both lung and prostate cancers and a decreasing frequency of breast cancer and other cancer types. Furthermore, patients prescribed radiotherapy in 1999 and 2001 had a poorer performance status (median of 60) than patients seen in 2004 and 2005 (median of 70) ($P < 0.0001$, Table 1).

Table 2 presents the univariate relationship between individual clinical and demographic variables and single-fraction radiotherapy. As shown, patients treated with single-fraction radiotherapy were significantly older (mean age 68.26 years) than patients treated with multiple fractions (mean age 65.64 years). For each increasing year of age, patients had 1.02 times greater the odds of receiving single-fraction radiation. Patients with prostate cancer had 1.623 times the odds of receiving single-fraction radiation, compared with patients with lung cancer. There were no significant differences in the use of single or multiple fractions for patients with breast or other types of cancer, with odds ratios of 0.767 and 0.981, respectively (Table 2). Patients who had a higher KPS had lower odds of receiving single-fraction radiation than patients with a poorer performance status (odds ratio = 0.984, 95% confidence interval 0.972–0.996). Also, patients who lived ‘very distant’ from the treatment centre had 1.951 times the odds (95% confidence interval 1.050–3.864) of receiving a single fraction of radiotherapy compared with patients who lived ‘near’ the cancer centre. Overall, there were significant differences in the use of single-fraction radiotherapy by bony sites of metastases ($P < 0.0001$); single
Table 1 – Clinic activity, demographic, disease and treatment characteristics of patients by year of radiotherapy treatment

|                     | Overall   | 1999 (n = 169; 24.4%) | 2001 (n = 186; 26.8%) | 2004 (n = 236; 34.1%) | January to July 2005 (n = 102; 14.7%) | P value |
|---------------------|-----------|-----------------------|-----------------------|-----------------------|----------------------------------------|---------|
| Clinical activity   | 693       | 169 (24.4%)           | 186 (26.8%)           | 236 (34.1%)           | 102 (14.7%)                            | 0.05264 |
| Patients prescribed radiotherapy | 965       | 229 (23.7%)           | 245 (25.4%)           | 346 (35.9%)           | 145 (15.0%)                            | 0.03169*|
| Courses of radiotherapy prescribed |          |                       |                       |                       |                                        |         |
| Gender              |           |                       |                       |                       |                                        |         |
| Male                | 395 (57.0%) | 82 (48.5%)            | 110 (59.1%)           | 136 (57.6%)           | 67 (65.7%)                             | 0.0370* |
| Female              | 298 (43.0%) | 87 (51.5%)            | 76 (40.9%)            | 100 (46.4%)           | 35 (34.3%)                             |         |
| Age at radiation (in years) |          |                       |                       |                       |                                        | 0.7314  |
| Mean ± standard deviation | 67.4 ± 11.3 | 66.8 ± 10.2           | 67.5 ± 10.8           | 67.2 ± 11.8           | 68.4 ± 12.7                            |         |
| Median (range)      | 69 (31–95) | 68 (31–88)            | 69 (35–88)            | 69.5 (33–95)          | 69.5 (31–94)                           |         |
| Primary cancer site |           |                       |                       |                       |                                        |         |
| Lung                | 173 (25.0%) | 33 (19.5%)            | 45 (24.2%)            | 61 (25.8%)            | 34 (33.3%)                             | 0.0045* |
| Breast              | 159 (22.9%) | 49 (29.0%)            | 37 (19.9%)            | 52 (22.0%)            | 21 (20.6%)                             |         |
| Prostate            | 168 (24.2%) | 31 (18.3%)            | 41 (22.0%)            | 72 (30.5%)            | 24 (23.5%)                             |         |
| Others              | 193 (27.8%) | 56 (33.1%)            | 63 (33.9%)            | 51 (21.6%)            | 23 (22.5%)                             |         |
| Karnofsky Performance Status score |          |                       |                       |                       |                                        |         |
| Number of evaluable patients | 590 (85.1%) | 163 (96.4%)           | 151 (81.2%)           | 212 (89.8%)           | 64 (62.7%)                             | <0.0001*|
| Median (range)      | 60 (10–90) | 60 (10–90)            | 60 (30–90)            | 70 (30–90)            | 70 (40–90)                             |         |
| Distance between residence and cancer centre (km) |          |                       |                       |                       |                                        |         |
| Number of evaluable patients | 688 (99.3%) | 167 (98.8%)           | 186 (100.0%)          | 235 (99.6%)           | 100 (98.0%)                            |         |
| Continuous          |           |                       |                       |                       |                                        | 0.6543  |
| Mean ± standard deviation | 43.2 ± 49.3 | 40.5 ± 45.2           | 46.9 ± 50.9           | 42.9 ± 51.2           | 41.8 ± 48.5                            |         |
| Median (range)      | 25.1 (1.1–442.0) | 26.7 (1.5–376.0)    | 26.8 (1.9–442.0)     | 24.2 (1.1–402.0)     | 22.1 (4.7–343.0)                      |         |
| Ordinal             |           |                       |                       |                       |                                        | 0.7444  |
| Near (0 to <40 km)  | 455 (66.1%) | 115 (68.9%)           | 115 (61.8%)           | 159 (67.7%)           | 66 (66.0%)                             |         |
| Intermediate (>40 to <80 km) | 120 (17.4%) | 29 (17.4%)            | 32 (17.2%)            | 39 (16.6%)            | 20 (20.0%)                             |         |
| Distant (>80 to <120 km) | 113 (16.4%) | 12 (7.2%)             | 21 (11.3%)            | 16 (6.8%)             | 6 (6.0%)                               |         |
| Very distant (>120 km) | 55 (8.0%)  | 11 (6.6%)             | 18 (9.7%)             | 21 (8.9%)             | 8 (8.0%)                               |         |
| Dichotomous         |           |                       |                       |                       |                                        | 0.3404  |
| Near (0 to <45 km)  | 491 (71.4%) | 123 (73.6%)           | 124 (66.7%)           | 174 (74.0%)           | 70 (70.0%)                             |         |
| Distant (>45 km)    | 187 (28.6%) | 44 (26.4%)            | 62 (33.3%)            | 61 (26.0%)            | 30 (30.0%)                             |         |
| Site of radiotherapy |           |                       |                       |                       |                                        |         |
| Spine               | 217 (31.3%) | 50 (29.6%)            | 61 (32.8%)            | 63 (26.7%)            | 43 (42.2%)                             | 0.1732  |
| Pelvis              | 174 (25.1%) | 40 (23.7%)            | 56 (30.1%)            | 58 (24.6%)            | 20 (19.6%)                             |         |
| Ribs, scapula, sternum and clavicle | 77 (11.1%)  | 19 (11.2%)            | 19 (10.2%)            | 26 (11.0%)            | 13 (12.8%)                             |         |
| Limbs, hips and shoulders | 210 (30.3%) | 56 (33.1%)            | 48 (25.8%)            | 83 (35.2%)            | 23 (22.6%)                             |         |
| Cranium, hemi-body  | 15 (2.2%)  | 4 (2.4%)              | 2 (1.1%)              | 6 (2.5%)              | 3 (2.9%)                               |         |
| Year of certification of radiation oncologist |          |                       |                       |                       |                                        | 0.0001  |
| 1970–1979           | 177 (25.7%) | 48 (28.4%)            | 36 (19.4%)            | 65 (27.5%)            | 28 (28.3%)                             |         |
| 1980–1989           | 185 (26.8%) | 48 (28.4%)            | 66 (35.5%)            | 45 (19.1%)            | 26 (26.3%)                             |         |
| 1990–1999           | 250 (36.2%) | 73 (43.2%)            | 68 (36.6%)            | 84 (35.6%)            | 25 (25.2%)                             |         |
| 2000–2006           | 78 (11.3%)  | 0 (0.0%)              | 16 (8.6%)             | 42 (17.8%)            | 20 (20.2%)                             |         |

*Statistical significance using the chi-square test for proportions and the ANOVA test for continuous variables, defined as P ≤ 0.05.
fractions were used more frequently to irradiate the limbs, hips, pelvis and ribs compared with treatments to the spine (Table 2). There were significant differences in the prescription of single- or multiple-fraction radiation according to the year of certification of the radiation oncologists. Oncologists certified in the 1970s and 1980s were more likely to prescribe single-fraction radiation than those certified in the 2000s (odds ratio $= 4.07$ and $2.50$, respectively). However, there was no difference in the prescription patterns of oncologists certified in the 1990s compared with their year 2000s counterparts. Gender was not found to be associated with single-fraction radiation (Table 2).

The results of the multivariable logistic regression analyses are also presented in Table 2. After adjusting for gender, age, primary cancer site, KPS, distance travelled (ordinal measurement), site of radiotherapy, and year of certification of the radiation oncologist, there was a significantly increased likelihood of single-fraction radiation being prescribed after 1999. The odds of using single-fraction radiation were about 1.5 times greater overall than in 1999 (Table 2). The increased use of single-fraction radiation was observed in 2002, 2004 and 2005. KPS, the site of radiation, and the year of certification of the oncologist were also significantly associated with the dose-fractionation regimen. Treatments to the pelvis had 5.6 times the odds of receiving single-fraction radiation, whereas treatments to the ribs, scapula, sternum and clavicle had about 3.2 times the odds of receiving single-fraction radiation compared with treatments to the spine. Also, treatments to the limbs, hips and shoulders had 1.9 times the odds of receiving single-fraction radiation compared with treatments to the spine. After controlling for age, the primary cancer site overall was not found to be related to single-fraction radiation, although prostate cancer patients had a greater likelihood (odds ratio $= 2.089$) of being prescribed single-fraction radiation compared with other cancer sites. Oncologists trained in earlier years (i.e. 1970s and 1980s) had significantly higher odds of prescribing single-fraction radiation than oncologists trained later. There was no collinearity present in the multivariable model, with variance inflation factors ranging from 1.00853 to 1.12102. The results of the Hosmer–Lemeshow goodness-of-fit test did not indicate any evidence of gross lack of fit of the model ($P = 0.1489$).

Discussion

This study provides insight into the knowledge translation of empirical evidence from RCTs to the palliative radiotherapy clinical setting. On the basis of our review of practice in the RRRP, the use of single-fraction radiation did increase significantly over time, particularly in 2001 and 2004 after the publication of the two large RCTs [3, 8] and the two meta-analyses [4, 16]. Similarly, a rapid change in the pattern of practice of concurrent chemotherapy and radiation in cervical cancer in Ontario has also been shown in response to the publication of RCTs and recommendations of the National Cancer Institute [40].

There was a decline in the prescription of single-fraction radiation in 2005 compared with 2001 and 2004, although the odds of administration of single-fraction radiotherapy were significantly higher than in 1999 (odds ratio 2.236, 95% confidence interval 1.079–4.633). This may not be a true reflection of the prescription patterns of oncologists in the RRRP in 2005. First, data were only collected until 31 July 2005, resulting in few courses of radiotherapy during the 2005 time period included in the study compared with other years. As such, cases have been overlooked, which may
Table 2 – Univariate and multivariable logistic regression analyses examining the relationship between demographic and clinical variables and the use of single-dose fractionation for bone metastases

| Year of treatment       | Univariate logistic regression |  | Multivariable logistic regression* |
|-------------------------|-------------------------------|---|-----------------------------------|
|                         | Single fraction (n = 451, 65.1%) | Multiple fractions (n = 242, 34.9%) | Univariate odds ratio (95% CI) | P value | Adjusted odds ratio (95% CI) | P value |
| January to December 1999| 0.0002                         | 1.515 (1.241–1.849) | <0.0001                      |
| January to December 2001| Referent                       | Referent | 2.619 (1.539–4.546) | 0.0004                      |
| January to December 2004| 2.299 (1.491–3.569) | 0.0002 | 3.473 (2.049–5.886) | <0.0001                      |
| January to August 2005  | 1.848 (1.117–3.091) | 0.0179 | 2.236 (1.079–4.633) | 0.0304                      |
| **Gender**              |  |  |  |  |  |  |
| Male (n = 395)          | 1.136 (0.829–1.556) | 0.4270 | 0.604 (0.347–1.053) | 0.0756                      |
| Female (n = 298)        | Referent                       | Referent | 1.016 (0.997–1.035) | 0.1011                      |
| **Age (years)**         |  |  |  |  |  |  |
| Mean ± standard deviation| 68.3 ± 11.2 | 65.6 ± 11.2 | 1.021 (1.007–1.035) | 0.0037                      |
| Median (range)          | 70 (31–95) | 66 (33–88) | 1.016 (0.997–1.035) | 0.1011                      |
| **Primary cancer site** |  |  |  |  |  |  |
| Lung (n = 173)          | 1.0175                         | 1.004 (0.850–1.184) | 0.0555                      |
| Breast (n = 159)        | 0.767 (0.492–1.193) | 0.2398 | 0.763 (0.392–1.487) | 0.4273                      |
| Prostate (n = 168)      | 1.623 (1.022–2.597) | 0.0413 | 2.089 (1.106–3.945) | 0.0231                      |
| Others (n = 193)        | 0.981 (0.639–1.505) | 0.9316 | 0.951 (0.559–1.620) | 0.8539                      |
| **Karnofsky Performance Status score** |  |  |  |  |  |  |
| Number patients evaluated | 363 (80) | 227 (94) | 0.984 (0.972–0.996) | 0.0076                      |
| Mean ± standard deviation| 62.1 ± 14.6 | 65.3 ± 13.5 | 0.982 (0.967–0.996) | 0.0134                      |
| Median (range)          | 60 (10–90) | 70 (30–90) | 1.198 (0.979–1.465) | 0.4949                      |
| **Distance between residence and cancer centre (km)** |  |  |  |  |  |  |
| Number patients evaluated | 447 (99) | 227 (94) | 1.198 (0.979–1.465) | 0.4949                      |
| Continuous              |  |  |  |  |  |  |
| Mean ± standard deviation| 45.4 ± 51.8 | 39.2 ± 43.9 | 1.003 (0.999–1.006) | 0.1166                      |
| Median (range)          | 26.7 (1.1–402.0) | 24.0 (1.9–442.0) | 1.198 (0.979–1.465) | 0.4949                      |
| **Ordinal**             |  |  |  |  |  |  |
| Near (0 to <40 km)      | 0.1644                         |  |  |  |
| Intermediate (40 to >80 km) | 74 (61.2%) | 46 (38.3%) | 0.907 (0.601–1.379) | 0.6432                      |
| Distant (>80 to <120 km) | 1.158 (0.647–2.142) | 0.6279 | 1.096 (0.522–2.300) | 0.8089                      |
| Very distant (>120 km)  | 1.951 (1.050–3.864) | 0.0427 | 1.801 (0.834–3.886) | 0.1341                      |
| **Dichotomous**         |  |  |  |  |  |  |
| Near (0 to <45 km)      | 0.171 (0.827–1.669) | 0.3763 |  |  |
| Distant (>45 km)        | Referent                       | Referent |  |  |
| **Site of radiotherapy**|  |  |  |  |  |  |
| Spine (n = 217)         | <0.0001                         | 1.392 (1.200–1.614) | <0.0001                      |
| Limbs, hips, shoulders  | 1.729 (1.148–2.618) | 0.0092 | 1.875 (1.108–3.173) | 0.0192                      |
| Pelvis (n = 174)        | 2.527 (1.443–4.577) | 0.0016 | 5.626 (2.676–11.824) | <0.0001                      |
| Ribs, scapula, sternum, | 2.562 (1.709–3.873) | 0.0001 | 3.158 (1.990–5.240) | <0.0001                      |
| clavicle (n = 77)       | 1.014 (0.352–2.984) | 0.9798 | 0.725 (0.219–2.397) | 0.5981                      |
| Others (skull, hemi-body)| 8 (53) | 7 (47) | 1.014 (0.352–2.984) | 0.9798                      |
| (n = 15)                | Referent                       | Referent |  |  |
| **Year of certification**|  |  |  |  |  |  |
| of radiation oncologist  |  |  |  |  |  |  |
| 1970–1979 (n = 177)     | <0.0001                         | 4.074 (2.227–7.541) | <0.0001                      |
| 1980–1984 (n = 114)     | 6.356 (3.076–13.131) | <0.0001 |  |  |
In a similar palliative radiation clinic, Haddad published a study [41] that has examined the change in use of single-fraction radiotherapy, as they are not paid per fraction of radiation delivered. There are no financial incentives for Canadian radiation oncologists to prescribe more than one fraction of radiotherapy, and as a result, the use of single-fraction radiotherapy is generally increased between 1998 and 2000, from 37 to 43%, but declined again in 2001 to 26%. As indicated in Fig. 1, the relative proportion of use of single-fraction radiotherapy was much higher in the RRRP during the same period (50.9 and 70.8% of all radiotherapy cases in 1999 and 2001, respectively).

There are no known reasons to account for the differences in use of single-fraction radiotherapy in the PROP or RRRP clinics. In 2001, a survey of radiation oncologists at PMH was conducted to investigate factors guiding the prescription and fractionation practices for bone metastases [42]. The survey found that only 28% would prescribe single-fraction radiation for bone metastases. Eighty-eight percent and 40% reported using 8 Gy and 20 Gy/five fractions, respectively, to guide their choice of dose-fractionation schedule. Less than 10% of the oncologists used the location of the lesion in the vertebrae or weight-bearing bones. A survey conducted in the UK in the 1980s found that radiation oncologists who normally prefer single-fraction radiotherapy for the palliation of bone metastases would use multiple fractions for cases involving younger age (e.g., ≤ 40 years), cervical spine metastases, neurological symptoms associated with spinal metastases, diagnoses of a single bone lesion, and lytic metastases [21].

To our knowledge, however, there has been only one published study [41] that has examined the change in use of single-fraction radiotherapy for bone metastases over time in a similar palliative radiation clinic. Haddad et al. [41] conducted a review of dose fractionations used in the treatment of bone metastases at the Palliative Radiation Oncology Program (PROP) at Princess Margaret Hospital (PMH) in Toronto, Ontario. Like RRRP, PROP provides quick access to palliative radiotherapy at a large radiation treatment centre. PROP patient profiles were comparable with those of the RRRP in terms of primary cancer site, gender, age, and skeletal sites of metastases. Overall, single-fraction radiotherapy was used with greater frequency among the 693 evaluated RRRP patients when compared with the 882 PROP patients (65% vs 32%, respectively) [41]. In both clinical settings, the most frequently prescribed single- and multiple-fraction treatment regimens were a single 8 Gy and 20 Gy/five fractions, respectively. In PROP, the use of single-fraction radiotherapy generally increased between 1998 and 2000, from 37 to 43%, but declined again in 2001 to 26%. As indicated in Fig. 1, the relative proportion of use of single-fraction radiotherapy was much higher in the RRRP during the same period (50.9 and 70.8% of all radiotherapy cases in 1999 and 2001, respectively).

| 1980–1989 (n = 185) | 1990–1999 (n = 250) | 2000–2006 (n = 78) |
|---------------------|---------------------|---------------------|
| 143 (77)            | 112 (45)            | 45 (58)             |
| 2 (23)              | 138 (55)            | 33 (42)             |

**Table 2 — (continued)***

|  | Single fraction (n = 451, 65.1%) | Multiple fractions (n = 242, 34.9%) | Univariate logistic regression | Multivariable logistic regression* |
|---|---------------------------------|-----------------------------------|-------------------------------|-----------------------------------|
| 1980–1989 (n = 185) | 143 (77) | 42 (23) | 2.497 (1.417–4.405) | 0.0015 |
| 1990–1999 (n = 250) | 112 (45) | 138 (55) | 0.595 (0.354–0.992) | 0.0477 |
| 2000–2006 (n = 78) | 45 (58) | 33 (42) | Referent | Referent |

*P < 0.0001 for overall multivariable logistic regression model, after adjusting for gender, age, distance, primary cancer site, Karnofsky Performance Status, and year of certification of radiation oncologist. CI, confidence interval.
respectively, compared with 2.619 and 3.473 for treatments in 1999 and 2001, respectively). It is not expected that there is a cohort effect, where more experienced oncologists who are trained in earlier years may be more likely to give single-fraction radiotherapy or be more likely to base clinical practice on empirical evidence. More experienced oncologists trained in earlier years may be more confident in knowing and applying the results of empirical evidence to clinical practice. However, the observed differences in the prescription patterns between oncologists warrant further investigation. It is difficult to confidently ascertain whether the increased use of single-fraction radiotherapy over time in the RRRP was due to the effect of empirical evidence and recommendations in the literature or due to other factors, such as personal preferences of the radiation oncologists, patient preferences, or other patient and tumour-related characteristics not examined here.

This study was limited by factors beyond the control of the researchers and resources of the study. Because one course of palliative radiation was randomly selected for patients, some cases may have been overlooked. It is difficult to know whether previous courses of radiotherapy confounded the use of single or multiple fractions for all subsequent treatments for bone metastases. Similar to the PMH review [41], estimates of patient survival and life expectancy by the treating radiation oncologist were not consistently available in patient records and were not included as potential covariates in the dose-fractionation prescription. Data on waiting times from referral to radiotherapy consultation were not collected in this study. It is hypothesised that this variable could influence the use of single or multiple fractions across time, depending on the pressure of radiation waiting times within the radiotherapy department as well as within the RRRP clinic. In the PMH review, waiting times for radiation were not found to influence the use of single or multiple fractions [41]. Also, specific tumour characteristics were not recorded, such as the lesion type (lytic, blastic, or mixed), the date of diagnosis of the primary cancer site and bone metastases, the number of bony lesions, or other sites of metastases and the extent of disease, as these data were inconsistently available in electronic patient records. Furthermore, data on the field size of radiation delivered were not collected in this study, which could have influenced the oncologist’s decision for dose-fractionation choice. These disease-related factors may have influenced the dose-fractionation prescription patterns. Lastly, data on radiation oncologist sub-specialities were not collected in this study.

Conclusions

Overall, 60% of courses of palliative radiotherapy for bone metastases in our programme were prescribed as single fractions. The results of this study suggest that practice significantly changed in the RRRP after the publication of influential RCTs and recommendations for treatment. There was an increase in the prescription of single-fraction radiotherapy for painful bone metastases over time in the RRRP. The most significant changes followed the publication of the two large RCTs and two meta-analyses confirming equivalence in pain relief between single and multiple fractions in 1999 and 2004, respectively. Potential contributing factors to dose-fractionation schedules included the site of bone metastases and physician-related factors. An obligation exists to use the most cost-effective treatment plan that provides equivalent outcomes [30] in order to provide the best medical care and to optimise resources in both publicly and privately funded regions of the world. Recently, increased use of single-fraction radiotherapy in the treatment of bone metastases has been shown to reduce overall radiotherapy workload in the UK by 6% [34]. Reductions in radiotherapy workload allow for an increased availability of radiation resources, which has the potential to reduce radiation waiting times for patients who have the potential for cure, where the time of access to radiation is essential to prevent tumour growth and metastasis [43]. Patients may also benefit from the use of single-fraction radiation, being spared additional travelling and treatment time. Many studies have already promoted and advocated the use of single-fraction radiation [5, 44–46]. We also advocate the use of single-fraction radiation, but acknowledge the need for an individual case-based management for complicated bone metastases. Further research in the management of patients with complicated bone metastases is needed to determine when the use of multiple fractions is most appropriate, such as the controversy in the dose fractionation used for neuropathic pain or spinal cord compression.

Acknowledgements. This study was supported by the Michael and Karen Goldstein Cancer Research Fund and the Odette Cancer Centre Radiation Program Fund. The study sponsors had no involvement in the study design, data collection, statistical analysis, interpretation of results, writing of the manuscript, or decisions to submit for publication. This work was presented in part at the 16th Annual Provincial Conference on Palliative and End-of-Life Care, April 2006, Toronto, Ontario, Canada.

Author for correspondence: E. Chow, Department of Radiation Oncology, Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. Tel: +416-480-4998; Fax: +416-480-6002; E-mail: Edward.Chow@sunnybrook.ca

Received 5 September 2007; received in revised form 19 December 2007; accepted 20 December 2007

References

1 Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 1997;21:129–183.
2 Needham PR, Hoskin PJ. Radiotherapy for painful bone metastases. Palliat Med 1994;8:95–104.
3 Steenland E, Leer J, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiatother Oncol 1999;52:101–109.
Changes in practice of radiotherapy prescription for bone metastases in RRPP

4 Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594–605.

5 Bentzen SM, Hoskin P, Roos D, et al. Fractionation radiotherapy for metastatic bone pain: evidence-based medicine or...? [Letter]. Int J Radiat Oncol Biol Phys 2000;46:681–685.

6 Ratanatharathorn V, Powers WE, Moss WT, et al. In response to Dr. Bentzen et al. [Letter]. Int J Radiat Oncol Biol Phys 2000;46:681–685.

7 Amichetti M, Orrù P, Madeddu A, et al. Comparative evaluation of two hypofractionated radiotherapy regimens for painful bone metastases. Tumori 2004;90:91–95.

8 Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999;52:111–121.

9 Cole DJ. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol (R Coll Radiol) 1989;1:59–62.

10 Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol 1997;45:109–116.

11 Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798–804.

12 Kaasa S, Brenne E, Fayers P, et al. Single fraction radiotherapy (Gy x 1) versus multiple fraction (3 Gy x 10) for treatment of painful bone metastases — a multi-centre randomised trial [Abstracts of the 18th UICC International Cancer Congress. 30 June–5 July 2002, Oslo, Norway]. Int J Cancer 2002;(Suppl 13):136 [abstract].

13 Kagei K, Suzuki K, Shirato H, et al. A randomized trial of single and multifraction radiotherapy for bone metastasis: a preliminary report. Gan No Rinsho 1990;36:2553–2558.

14 Nielsen OS, Bentzen SM, Sandberg E, et al. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 1998;47:233–240.

15 Pant MC, Singh B, Srivastava M, et al. Palliation of painful bone metastasis: the effect of 8 gy in single fraction compared to multi-fractionated radiotherapy. Int J Cancer 2002;100:513 [abstract].

16 Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy — a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003;15:345–352.

17 Wu JS, Wong RKS, Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases — an evidence-based practice guideline. BMC Cancer 2004;4:71.

18 of two osteosarcoma cases: a survey of current practices of care. Int J Radiat Oncol Biol Phys 1998;40:915–921.

19 Chow E, Danjoux C, Wong R, et al. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 2000;56:305–314.

20 Coia LR, Hanks GE, Martz K, et al. Practice patterns of palliative care for the United States 1984–1985. Int J Radiat Oncol Biol Phys 1988;14:1261–1269.

21 Cresslin AM, Marks A, Maher EJ. Why don’t British radiotherapists give single fractions of radiotherapy for bone metastases? Clin Oncol (R Coll Radiol) 1989;1:63–66.

22 Duncan G, Duncan W, Maher EJ. Patterns of palliative radiotherapy in Canada. Clin Oncol (R Coll Radiol) 1993;5:92–97.

23 Gupta T, Sarin R. Palliative radiation therapy for painful vertebral metastases — a practice survey. Cancer 2004;101:2892–2896.

24 Hartsell WF, Shah AB, Graney M, et al. Palliation of bone metastases in the USA: a survey of patterns of practice. Support Care Cancer 1998;6:175 [abstract].

25 Lawton PA, Maher EJ. Treatment strategies for advanced and metastatic cancer in Europe. Radiother Oncol 1999;22:1–6.

26 Lievens Y, Kesteloot K, Rijnders A, et al. Differences in palliative radiotherapy for bone metastases within Western European countries. Radiother Oncol 2000;56:297–303.

27 Maher EJ, Coia L, Duncan G, et al. Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys 1992;23:239–244.

28 Priestman TJ, Bullimore JA, Godden TP, et al. The Royal College of Radiologists' Fractionation Survey. Clin Oncol (R Coll Radiol) 1989;1:39–46.

29 Roos DE. Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review. Radiother Oncol 2000;56:315–322.

30 Stevens G, Firth I. Patterns of fractionation for palliation of bone metastases. Australas Radiol 1995;39:31–35.

31 Bradley NM, Husted J, Sey MS, et al. Review of the patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer 2007;15:373–385.

32 D’Souza DP, Martin DK, Purdy L, et al. Waiting lists for radiotherapy: a case study. BMC Health Serv Res 2001;1:3.

33 Pitch MI, Gray RE, Mcgowan T, et al. Travelling for radiation cancer treatment: patient satisfaction. Can Oncol Nurs J 2005;15:107–119.

34 Williams MV, James ND, Summers ET, et al. National survey of radiotherapy fractionation practice in 2003. Clin Oncol (R Coll Radiol) 2006;18:3–14.

35 Barton MB, Dawson R, Jacob S, et al. Palliative radiotherapy of bone metastases: an evaluation of outcome measures. J Eval Clin Pract 2001;7:47–64.

36 Szumacher E, Llewellyn-Thomas H, Franssen E, et al. Treatment of bone metastases with palliative radiotherapy: patients' treatment preferences. Int J Radiat Oncol Biol Phys 2005;61:1473–1481.

37 Danjoux C, Chow E, Drossos A, et al. An innovative rapid response radiotherapy program to reduce waiting time for palliative radiotherapy. Support Care Cancer 2006;14:38–43.

38 Mor V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale: an examination of its reliability and validity in a research setting. Cancer 1984;53:2002–2007.

39 Cody RP, Smith JK. Applied statistics and the SAS programming language, 5th edn. Amsterdam: Elsevier Science; 2006.

40 Barbera L, Paszat L, Thomas G, et al. The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation. Int J Radiat Oncol Biol Phys 2006;64(5):1389–1394.

41 Haddad P, Wong RKS, Pond GR, et al. Factors influencing single vs. multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol 2005;17:430–434.

42 Haddad P, Wong R, Wilson P, et al. Factors influencing the use of single versus multiple fractions of palliative radiotherapy for...
bone metastases: a 5-year review and comparison to a survey. *Int J Radiat Oncol Biol Phys* 2003;57:S278–S279 [abstract].

43 Mikeljevic JS, Haward R, Johnston C, et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. *Br J Cancer* 2004;90:1343–1348.

44 van der Linden YM, Leer JW. Impact of randomized trial-outcome in the treatment of painful bone metastases: patterns of practice among radiation oncologists. A matter of believers vs. non-believers? *Radiother Oncol* 2000;56:279–281.

45 Chow E, Lutz S, Beyene J. A single fraction for all, or an argument for fractionation tailored to fit the needs of each individual patient with bone metastases? *Int J Radiat Oncol Biol Phys* 2003;55:565–567.

46 Kachnic L, Berk L. Palliative single-fraction radiation therapy: how much more evidence is needed? *J Natl Cancer Inst* 2005;97:786–788.